Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LIPE | Q05469 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16182181 | 1.00 | NR1H2 (0.38) | NR1H2SMN1; SMN2GAATHRBMAPT | |
| SCHEMBL9965924 | 0.82 | NR1H2 (0.40) | NR1H2SMN1; SMN2GAATHRBMAPT | |
| SCHEMBL12835905 | 0.82 | NR1H2 (0.40) | NR1H2SMN1; SMN2GAATHRBMAPT | |
| SCHEMBL8283578 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2GAATHRBMAPTALDH1A1 | |
| SCHEMBL9963083 | 0.80 | NR1H2 (0.40) | NR1H2SMN1; SMN2GAATHRBMAPT | |
| SCHEMBL9965957 | 0.80 | KDM5A (0.48) | NR1H2SMN1; SMN2GAATHRBMAPT | |
| SCHEMBL14641877 | 0.80 | NR1H2 (0.40) | NR1H2SMN1; SMN2GAATHRBMAPT | |
| SCHEMBL12835643 | 0.80 | KDM5A (0.48) | NR1H2SMN1; SMN2GAATHRBMAPT | |
| SCHEMBL16182224 | 0.80 | KDM5A (0.48) | NR1H2SMN1; SMN2GAATHRBMAPT | |
| SCHEMBL9965918 | 0.79 | SMN1; SMN2 (0.47) | NR1H2SMN1; SMN2GAATHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | NR1H2 122/4885SMN1; SMN2 3655/4885GAA 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.